A clinical analysis of radiotherapy combined with temozolomide for postoperative high-grade glioma

Abstract

Objective To assess the efficacy and safety of three-dimensional radiotherapy (3DRT) combined with temozolomide (TMZ) for postoperative high-grade glioma (HGG), and to explore the prognostic factors for HGG patients. Methods A retrospective analysis was performed on the clinical data of 111 patients with postoperative HGG who were admitted to our hospital and received 3DRT combined with TMZ from 2008 to 2015. The efficacy and safety of the treatment were evaluated. The survival rate was calculated by the Kaplan-Meier method and analyzed by the log-rank test. A multivariate prognostic analysis was performed using the Cox model. Results The 1-, 2-, and 3-year sample sizes, overall survival (OS) rates, and progression-free survival (PFS) rates were//, 83.5%/46.9%/35.6%, and 52.2%/34.7%/26.4%, respectively. The common adverse reactions during chemoradiotherapy were acute neurotoxicity, hematologic toxicity, hepatotoxicity, and gastrointestinal toxicity, most of which were tolerable. Pathological grade was an independent prognostic factor for OS and PFS rates (P=, ). Conclusions 3DRT combined with TMZ achieves satisfactory efficacy and safety in the treatment of patients with postoperative HGG. Pathological grade is an independent prognostic factor for patients with postoperative HGG. Key words: High grade glioma/radiotherapy; Radiotherapy, Three-dimensional; High grade glioma/chemotherapy; Temozolomide